Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02241369 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02241369: Completed Phase 1 study, sponsored by Inovio Pharmaceuticals.
NCT02241369 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02241369, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a Phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3106 alone or in combination with INO-9012 DNA vaccines delivered by Electroporation to subjects with HPV6 associated aerodigestive precancerous lesions and malignancies.
Interventions
- BIOLOGICAL INO-3106, INO-9012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-09 |
| Phase | Phase 1 |
What the finished NCT02241369 record still lists
NCT02241369 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which INO-3106, INO-9012 is the first listed.
NCT02241369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02241369 about?
NCT02241369 is a clinical study titled "Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies". This is a Phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3106 alone or in combination with INO-9012 DNA vaccines delivered by Electroporation to subjects with HPV6 associated aerodigestive precancerous lesions and malignancies.
What is the current status of trial NCT02241369?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-05. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02241369?
The interventions under investigation include: INO-3106, INO-9012 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02241369?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02241369's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia